CO5550450A2 - Derivados de 1-acil-pirrolidina para el tratamiento de infec ciones virales - Google Patents

Derivados de 1-acil-pirrolidina para el tratamiento de infec ciones virales

Info

Publication number
CO5550450A2
CO5550450A2 CO05038997A CO05038997A CO5550450A2 CO 5550450 A2 CO5550450 A2 CO 5550450A2 CO 05038997 A CO05038997 A CO 05038997A CO 05038997 A CO05038997 A CO 05038997A CO 5550450 A2 CO5550450 A2 CO 5550450A2
Authority
CO
Colombia
Prior art keywords
alkyl
aryl
heteroaryl
hydrogen
heteroarylalkyl
Prior art date
Application number
CO05038997A
Other languages
English (en)
Spanish (es)
Inventor
David Haigh
Charles David Hartley
Peter David Howes
Martin John Slater
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224774A external-priority patent/GB0224774D0/en
Priority claimed from GB0229470A external-priority patent/GB0229470D0/en
Priority claimed from GB0317141A external-priority patent/GB0317141D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5550450A2 publication Critical patent/CO5550450A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CO05038997A 2002-10-24 2005-04-25 Derivados de 1-acil-pirrolidina para el tratamiento de infec ciones virales CO5550450A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0224774A GB0224774D0 (en) 2002-10-24 2002-10-24 Compounds
GB0229470A GB0229470D0 (en) 2002-12-18 2002-12-18 Compounds
GB0317141A GB0317141D0 (en) 2003-07-22 2003-07-22 Compounds

Publications (1)

Publication Number Publication Date
CO5550450A2 true CO5550450A2 (es) 2005-08-31

Family

ID=32180212

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05038997A CO5550450A2 (es) 2002-10-24 2005-04-25 Derivados de 1-acil-pirrolidina para el tratamiento de infec ciones virales

Country Status (18)

Country Link
US (1) US7304087B2 (enExample)
EP (1) EP1554274B1 (enExample)
JP (1) JP2006506455A (enExample)
KR (1) KR20050057670A (enExample)
AR (1) AR041816A1 (enExample)
AT (1) ATE418554T1 (enExample)
AU (1) AU2003276172A1 (enExample)
BR (1) BR0315417A (enExample)
CA (1) CA2503471A1 (enExample)
CO (1) CO5550450A2 (enExample)
DE (1) DE60325498D1 (enExample)
IS (1) IS7851A (enExample)
MA (1) MA27524A1 (enExample)
MX (1) MXPA05004435A (enExample)
NO (1) NO20052472L (enExample)
PL (1) PL376454A1 (enExample)
TW (1) TW200418848A (enExample)
WO (1) WO2004037818A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304494D0 (en) * 2003-02-27 2003-04-02 Glaxo Group Ltd Compounds
GB0408995D0 (en) * 2004-04-22 2004-05-26 Glaxo Group Ltd Compounds
GB0423673D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
GB0423672D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
WO2006050035A1 (en) 2004-10-29 2006-05-11 Schering Corporation Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents
GB0519486D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519478D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519485D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519488D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
WO2008106166A2 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
MX2009011930A (es) 2007-05-04 2009-11-18 Vertex Pharma Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
US20090053175A1 (en) * 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
EP2272832A4 (en) 2008-04-28 2011-09-07 Asahi Kasei Pharma Corp PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
BRPI0917458A2 (pt) 2008-08-11 2015-12-01 Glaxosmithkline Llc composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
CN102176911B (zh) 2008-08-11 2014-12-10 葛兰素史密丝克莱恩有限责任公司 新的腺嘌呤衍生物
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
RS53745B1 (sr) 2010-02-10 2015-06-30 Glaxosmithkline Llc 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on-maleat
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
ES2917887T3 (es) 2014-11-13 2022-07-12 Glaxosmithkline Biologicals Sa Derivados de adenina que son útiles en el tratamiento de enfermedades alérgicas u otras afecciones inflamatorias
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
JP2022533390A (ja) 2019-05-16 2022-07-22 スティングセラ インコーポレイテッド オキソアクリジニル酢酸誘導体および使用方法
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5687396A (en) 1995-04-21 1996-11-07 Novarits Ag N-aroylamino acid amides as endothelin inhibitors
AU1804299A (en) 1997-12-08 1999-06-28 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
EP1051104B1 (en) 1998-01-26 2008-04-09 Massachusetts Institute Of Technology Fluorescence imaging endoscope
WO1999054299A1 (en) 1998-04-23 1999-10-28 Abbott Laboratories Pyrrolidines as inhibitors of neuraminidases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1118287B1 (de) * 2000-01-21 2004-11-24 Alois Ing. Sampl Steckbares Regalsystem
EP1278743A4 (en) 2000-05-05 2003-05-14 Smithkline Beecham Corp NEW ANTI-INFECTIOUS ACTIVE SUBSTANCES
JP2004536779A (ja) 2000-11-20 2004-12-09 サイオス インコーポレイテッド p38キナーゼのインドール型阻害剤
JP2005511574A (ja) 2001-10-26 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー Nachrアゴニストとしてのn−アザビシクロ−置換ヘテロ二環式カルボキサミド
WO2003037893A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited Acyl dihydro pyrrole derivatives as hcv inhibitors
US20060167702A1 (en) 2002-10-28 2006-07-27 Pierre-Paul Jodoin Method of preventing theft to vehicles using intensive marking

Also Published As

Publication number Publication date
WO2004037818A1 (en) 2004-05-06
AU2003276172A1 (en) 2004-05-13
MA27524A1 (fr) 2005-09-01
PL376454A1 (en) 2005-12-27
US20060258720A1 (en) 2006-11-16
CA2503471A1 (en) 2004-05-06
DE60325498D1 (de) 2009-02-05
US7304087B2 (en) 2007-12-04
MXPA05004435A (es) 2005-07-26
EP1554274A1 (en) 2005-07-20
KR20050057670A (ko) 2005-06-16
NO20052472L (no) 2005-05-23
AR041816A1 (es) 2005-06-01
ATE418554T1 (de) 2009-01-15
BR0315417A (pt) 2005-08-16
IS7851A (is) 2005-05-19
JP2006506455A (ja) 2006-02-23
EP1554274B1 (en) 2008-12-24
TW200418848A (en) 2004-10-01

Similar Documents

Publication Publication Date Title
AR041816A1 (es) Compuesto de acil-pirrolidina, su uso para preparar una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para prepararlo
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
ATE320252T1 (de) 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäuream d derivate als hsp90 inhibitoren zur behandlung von krebs
CY1112706T1 (el) Παραγωγα 4-βενζυλαμινο-1-καρβοξυακυλ-πιπεριδινης ως αναστολεις της cετρ, χρησιμοι για τη θεραπεια ασθενειων οπως η υπερλιπιδαιμια ή η αρτήριοσκληρωση
PL2229356T3 (pl) 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
EA200600509A1 (ru) Соединения пиримидотиофена
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
EA201290401A1 (ru) Азотсодержащее гетероциклическое соединение и сельскохозяйственный фунгицид
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
WO2009109991A3 (en) Novel hydrazide containing tyrosine kinase inhibitors
ATE556085T1 (de) Phosphoramiditverbindung und verfahren zur herstellung von oligo-rna
AR073932A1 (es) Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
CY1109220T1 (el) Παραγωγα ν-ακυλαμινοβενζολιου ως εκλεκτικοι αναστολεις της οξειδασης μονοαμινης β
EA200500268A1 (ru) Производные диоксан-2-алкилкарбаматов, способ их получения и применение в терапии
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR066606A1 (es) Compuestos de heteroarilamida pirimidona
AR041297A1 (es) Derivados de 4-pirrolidino- fenil- bencil eter
NO20052976L (no) Fosfodiesterase-4-inhibitorer.
AR083501A1 (es) 1-(heterociclo carbonil)piperidinas
DE602005025251D1 (de) Verfahren zur herstellung eines 2-ethylaminopyridinderivats
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
EA200401482A1 (ru) Ненуклезидные ингибиторы обратной транскриптазы
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений

Legal Events

Date Code Title Description
FC Application refused